Also known as: AOA Dx Inc.
Blood Test for Early Detection of Ovarian Cancer
Company is active
Event Year: 2021
Company is active
Event Year: 2021
AOA Dx is at the forefront of revolutionizing early-stage cancer detection for women. Through groundbreaking research in glycolipids and the application of proprietary biomarker technology, AOA Dx is developing advanced blood tests designed for the early and accurate detection of ovarian cancer. Their innovative approach promises to significantly improve outcomes for women at risk.
AOA Dx is at the forefront of revolutionizing early-stage cancer detection for women. Through groundbreaking research in glycolipids and the application of proprietary biomarker technology, AOA Dx is developing advanced blood tests designed for the early and accurate detection of ovarian cancer. Their innovative approach promises to significantly improve outcomes for women at risk.
Total Raised: Unknown (Y Combinator backed)
Last Round: Summer 2021
Total Raised: Unknown (Y Combinator backed)
Last Round: Summer 2021
Healthcare
Healthcare
Healthcare -> Diagnostics
Healthcare -> Diagnostics
Team size: 25
Hiring: No
Team size: 25
Hiring: No
